Abstract:
PROBLEM TO BE SOLVED: To provide a single-step, one-pot process to obtain zotarolimus and other rapamycin derivatives on large scale.SOLUTION: Dried rapamycin is dissolved in isopropylacetate. After cooling and 2,6-lutidine addition, triflic anhydride is slowly added at -30°C. Salts are removed by filtration. Tetrazole, followed by a tert-base diisopropylethylamine is added. After incubation at room temperature, the product is concentrated and purified by a silica gel column using THF/heptane as an eluant. The product is collected, concentrated, and purified using an acetone/heptane column. The product-containing fractions are concentrated. The product is dissolved in t-BME and precipitated with heptane. The solids are dissolved in acetone and treated with butylated-hydroxy toluene, and the solution is concentrated. The process is repeated twice with acetone to remove solvents. At least one stabilizing agent is added, such as BHT at 0.5% before drying.
Abstract:
PROBLEM TO BE SOLVED: To provide a one-pot synthesizing process to obtain zotarolimus and other rapamycin derivatives on large scale.SOLUTION: A dried rapamycin is dissolved in isopropyl acetate. The solution is cooled, and 2,6-Lutidine is added, followed by slowly adding trifluoromethanesulfonic anhydride at -30°C. Salts are then removed by filtration. Tetrazole, followed by a tert-base diisopropylethylamine is added. After incubation at room temperature, the product is concentrated and purified by a silica gel column using THF/heptane as eluant. The fractions containing the product are collected, concentrated, and purified again using an acetone/heptane column. The product containing fractions are concentrated. The product is dissolved in t-BME and precipitated with heptane. The solids are dissolved in acetone, treated with butylated-hydroxy toluene (BHT), and the solution concentrated. The process is repeated twice with acetone to remove solvents. At least one stabilizing agent is added, such as BHT at 0.5% before drying.
Abstract:
A single-step, one-pot process to obtain zotarolimus and other rapamycin derivatives on large scale that improves currently available syntheses. In one embodiment, dried rapamycin is dissolved in isopropylacetate . After cooling and 2,6-Lutidine addition, triflic anhydride is slowly added at -30° C. Salts are removed by filtration. Tetrazole, followed by a tert-base diisopropylethylamine is added. After incubation at room temperature, the product is concentrated and purified by a silica gel column using THF/heptane as eluant. The product is collected, concentrated, and purified using an acetone/heptane column. The product-containing fractions are concentrated. The product is dissolved in t-BME and precipitated with heptane. The solids are dissolved in acetone, treated with butylated-hydroxy toluene, and the solution concentrated. The process is repeated twice with acetone to remove solvents. At least one stabilizing agent is added, such as BHT at 0.5% before drying.
Abstract:
A single-step, one-pot process to obtain zotarolimus and other rapamycin derivatives on large scale that improves currently available syntheses. In one embodiment, dried rapamycin is dissolved in isopropylacetate . After cooling and 2,6-Lutidine addition, triflic anhydride is slowly added at -30° C. Salts are removed by filtration. Tetrazole, followed by a tert-base diisopropylethylamine is added. After incubation at room temperature, the product is concentrated and purified by a silica gel column using THF/heptane as eluant. The product is collected, concentrated, and purified using an acetone/heptane column. The product-containing fractions are concentrated. The product is dissolved in t-BME and precipitated with heptane. The solids are dissolved in acetone, treated with butylated-hydroxy toluene, and the solution concentrated. The process is repeated twice with acetone to remove solvents. At least one stabilizing agent is added, such as BHT at 0.5% before drying.
Abstract:
Formas cristalinas hidratadas, las formas cristalinas solvatadas y las formas cristalinas de (2S, 3S, 5S)-2-(2,6-dimetilfenoxiacetil) amin-3-hidroxi-5-(2-(1-tetrahidropirimid-2-onil)-3-metilbutanoil)amin-1,6-difenilhexano (lopinavir), asi como las formas substancialmente puras de todas las formas anteriormente mencionadas. El lopinavir es de utilidad en la inhibicion de la proteasa del VIH y la inhibicion de una infeccion por VIH.